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Poster Session I S297(DFS) was 28 months in AA and 17 months in non-AA (p 5
NS). Five patients (all non-AA) died, 4 of 5 due to progression
of disease. Response rates of AA patients treated with novel
agents followed by ASCT were then compared to 38 consecutive
historical AA patients receiving conventional induction chemo-
therapy followed by ASCT at our center. After utilizing novel
agents the ORR in AA patients increased from 56% to 89%
(p 5 0.02). Median DFS also improved from 21 to 28 months
(p 5 0.43). Our findings demonstrate that despite the AA popu-
lation having double the incidence of multiple myeloma, AA pa-
tients respond well to novel agents followed by ASCT. These
results also suggest that differences in long term survival between
AA and non-AA MM patients observed in previous studies could
be due to limited access to care rather than biologic causes.251
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Introduction: Stem cell transplantation (SCT) is a treatment option
for relapsed/refractory Non-Hodgkin’s lymphoma (NHL) patients.
Busulfan, cyclophosphamide, and etoposide (Bu/Cy/VP-16) has
been investigated as a conditioning regimen for allogeneic (alloSCT)
and autologous (auSCT), but its spectrum of early (\1 year) and late
(. 1 year) complications are not well characterized. We investigated
the complications experienced by patients at the Northwestern Uni-
versity transplanted with this regimen.
Methods:We performed a retrospective analysis of all relapsed/re-
fractory NHL patients who received SCT at our center with Bu/Cy/
VP-16 conditioning from 3/2003-6/2011.
Results: 25 patients with relapsed/refractory NHL who had SCT
with Bu/Cy/VP were identified. Median age was 49 (range: 28-
71). 13/25 (52%) patients had alloSCT and 12/25 (48%) had
auSCT. Median follow-up was 12 months (range: 5 days-96
months). Progression free survival was 71 6 10 % (95% confi-
dence interval (CI): 53-95%), overall survival was 77 6 9%
(95% CI: 61-98%), and disease free survival was 85% overall.
At less than 100 days post SCT, 4/25 (16%) patients died, 2 al-
loSCT and 2 auSCT. Causes included progressive disease, sepsis,
and respiratory failure. Peri-transplant morbidity (\100 days
post-transplant) most commonly included neutropenic fever
(22/25, 88%), mucositis (16/25, 64%), and elevated liver enzymes
(19/25, 76%), cardiovascular complications (8/25, 32%), pneumo-
nitis (7/25, 28%), and bacteremia (6/25, 24%). At 1 year follow-
up, 9/21 (43%) had persistently elevated liver enzymes, 8/21
(38%) had pneumonitis, and 2/21 (9.5%) had BOOP. At greater
than 1 year, 3/13 (23%) had persistently elevated liver enzymes
and 3/13 (23%) had BOOP. In the alloSCT population, 10/11
(91%) had acute graft versus host disease (GVHD) and 6/11
(55%) had chronic GVHD.
Conclusions: We conclude that Bu/Cy/VP-16 is a highly effective
conditioning regimen for NHL. Toxicity is not insignificant, as
100 day mortality was 16%. At least 2 of the 4 deaths occurred be-
cause of progressive disease, so selection of patients whose disease
is responsive to pre-transplant therapy would reduce the 100 day
mortality. Common peri-transplant complications included neutro-
penic fever, mucositis, and elevated liver enzymes. Given the high ef-
ficacy of this regimen with moderate long-term toxicity, in
chemotherapy responsive patients it can be considered as a viable
conditioning option prior to SCT.252
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Mortality associated with myeloablative conditioning has limited
its application in non-Hodgkin’s lymphoma (NHL). Myeloablation
with pharmacokinetically-targeted busulfan and fludarabine (t-i.v.
BuFlu) has been shown to be safe and effective in acute leukemia
and MDS, however there is very limited data in lymphoma. We as-
sessed retrospectively the outcomes of a consecutive series of 60 pa-
tients (pts) diagnosed with NHL who underwent allogeneic
hematopoietic cell transplant (allo-HCT) with t-i.v. BuFlu between
12/2004 and 8/2010. Thirty-seven pts weremale andmedian age was
54 yrs (range 27-68 yrs). Histologies included de novo or transformed
diffuse large B-cell lymphoma (DLBCL; n 5 12), follicular lym-
phoma (FL; n5 17), mantle cell lymphoma (MCL; n5 9), lympho-
blastic lymphoma (LBL; n 5 8), peripheral T-cell lymphoma
(PTCL; n 5 13) and marginal zone B-cell lymphoma (n 5 1). Me-
dian number of treatment lines was 3 (range 1-8). Median time
from diagnosis to transplant was 32 months (range 4.5- 177.5
months). At transplant, 28 (47%) pts were in CR, 22 (37%) in PR
and 10 (16%) had SD/PD. Average daily busulfan AUCwas targeted
based on pts age, concurrent comorbidities, or eligibility for a Bu
dose escalation trial: 3500 mmol x min/L in 13 pts, 5300 in 41 pts
and more than 5300 in 6 pts. Rituximab 375 mg/m2 on days +1
and +8 was added in 21 of 49 pts with CD20+ lymphomas. GVHD
prophylaxis included tacrolimus and methotrexate (n 5 39), myco-
phenolate (n 5 8) or sirolimus (n 5 13). Thirty-two pts received
grafts from matched sibling donors, 21 from matched unrelated,
and seven from mismatched (one antigen/allele) unrelated donors.
The cumulative incidence of grade 2-4 and grade 3-4 acute
GVHD at day 100 was 74% and 20% respectively. The cumulative
incidence of moderate-severe chronic GVHD at 2 years was 62%.
Progression free survival (PFS) at 3 years was 47.8% for all pts. Over-
all survival (OS) and CI of relapse at 3 year was 55.2% and 26.9% re-
spectively. OS and PFS were superior for pts with FL and LBL.
Patients in CR at transplant had an OS and CI of relapse at 3 years
of 60.7% and 10.7% respectively. NRM at day 100 and 3 year was
10% and 25.3% for the whole group. Main causes of death were re-
lapse (40%), infection (25%) and GVHD (14%). In conclusion, in
our series outcomes were better in patients with LBL and FL.
NRM was lower than historically reported with BuCy or TBI based
conditioning regimens but relapse continues to be the main cause of
failure.
Table. Progression free survival, Overall survival and Cumu-
lative incidence of relapse and Non-relapse mortality accord-
ing to Histologic Type
Follicular T cell DLBC Mantle Lymphoblastic All
n 5 17 n 5 13 n 5 12 n 5 9 n 5 8 n 5 60PFS
1 yr 70.5 30.7 33.3 55.6 62.5 51.7
3 yr 64.7 23.1 33.3 27.8 62.5 47.8
OS
1 yr 70.5 53.8 41.7 55.6 100 63.2
3 yr 64.7 46.1 41.7 55.6 66.7 55.2
CI RELAPSE
1 yr 5.9 38.5 33.3 22.2 37.5 25.0
3 yr 5.9 46.2 33.3 22.2 37.5 26.9
CI NRM
100 day 11.8 23.1 0 11.1 0 10.0
1 yr 29.4 30.8 33.3 22.2 0 23.3
3 yr 29.4 30.8 33.3 22.2 0 25.3
